A highly interactive forum
The Cancer Molecular Therapeutics Research Association Board of Directors is pleased to announce the location for the 2023 Molecular Therapeutics of Cancer Conference is at the
Watkins Glen Harbor Hotel in Watkins Glen, New York.
Save your dates for July 23 - 27, 2023.
Registration updates will be released here in the upcoming year. We are looking forward to it!
ABOUT THE CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION
The Full Story
Provides a dynamic platform for the most contemporary and controversial approaches to the treatment of cancer
Dedicates half of the formal presentation time to questions and answers to promote rigorous discussion
Welcomes an active dialog among investigators from industry, academia, government and, foundations
Enables informal and intimate (150 participants) networking for graduate students, postdoctoral fellows, residents and, early-stage and established investigators
Awards the top four poster presenters with the opportunity to orally present their research and attend next year’s conference free of charge
Builds on the legacy of more than two decades of annual conference
The 2022 CMTRA Conference was held in the Skamania Lodge in Stevenson, WA. We had an incredible time in July from 17- 21, 2022!
Congratulations to the following winners of the 2022 poster session:
See below photos from the event and the conference program.
Stay tuned for updates on the 2023 conference. These will be realeased soon!
The Cancer Molecular Therapeutics Research Association [CMTRA] was created in 2008 to organize and host the annual Molecular Therapeutics of Cancer meeting. The meeting objective is to provide a forum for presentation and discussion of contemporary research in the field of cancer drug development and therapy. Modeled after small Gordon-type conferences, the meeting provides an opportunity for young and established researchers to discuss and challenge current paradigms for cancer drug development and therapy, as well as a venue where novel ideas can be presented with anticipation of lively debate.
Cancelled due to the COVID-19 Pandemic
Cancelled due to the COVID-19 Pandemic
Officers & Board Members
MARTIN MCMAHON, PH.D.
Cumming-Presidential Professor of Cancer Biology & Senior Director for Preclinical Translation |
Huntsman Cancer Institute & Dept. of Dermatology | University of Utah | Salt Lake City, UT
LORI FRIEDMAN, PH.D.
Chief Scientific Officer | ORIC Pharmaceuticals | South San Francisco, CA
JAMES D. WINKLER, PH.D.
Chief Scientific Officer | OnKure Therapeutics
WILLIAM J. PLACZEK, PH.D.
Associate Professor | Department of Biochemistry and Molecular Genetics; Director | Central Alabama High-Field NMR Facility; Co-Director | Structural Biology Shared Facility, Cancer Center | The University of Alabama at Birmingham
PETER HOUGHTON, PH.D.
Director | Greehey Children's Cancer Research Institute | UT Health at San Antonio, San Antonio, TX
ROBERT KRAMER, PH.D.
RAKramer Consulting LLC | Newton, PA
MARY-ANN BJORNSTI, PH.D.
Professor & Chair Newman H Waters Chair of Clinical Pharmacology | Department of Pharmacology & Toxicology | University of Alabama at Birmingham
PHILLIP A. DENNIS, M.D., PH.D.
Vice President Lung Cancer | Sanofi Oncology
SHIVA MALEK, PH.D.
Global Head, Oncology | Novartis Institute of Biomedical Research
ZAHID H. SIDDIK, PH.D.
Professor of Medicine | Pharmacology Department of Experimental Therapeutics | MD Anderson Cancer Center | Houston, TX
ELI M. WALLACE, PH.D.
Chief Scientific Officer, Oncology | BridgeBio | Dallas, TX
BOB ABRAHAM, PH.D.
Executive Vice President | Head of Cancer Biology | Odyssey Therapeutics
Emeritus Board Members:
Alan Eastman, Ph.D. - Professor Emeritus | Norris Cotton Cancer Center | Dartmouth College | Hanover, NH
John A. Hickman, D.Sc. - Agon Consulting, Paris
Branimir I. Sikic, M.D. - Director | Stanford Clinical & Translational Research Unit; Co-director | Stanford University School of Medicine | Stanford, CA